The FDA approved the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (Tecartus, Kite) for treatment of adults with relapsed or refractory mantle cell lymphoma (MCL).
“Despite promising advances, there are still major gaps in treatment for patients with MCL who progress following initial therapy,” said Michael Wang, MD, the lead investigator on the ZUMA-2 trial that led to the approval, and a professor in the Department of Lymphoma and Myeloma at the